Azithromycin in high-risk, refractory chronic rhinosinusitus after endoscopic sinus surgery and corticosteroid irrigations: a double-blind, randomized, placebo-controlled trial.
Anastasios ManiakasMarc-Henri AsmarAxel Eluid RenteriaSmriti NayanSaud AlromaihLeandra Mfuna EndamJohn Sam SampalisMartin DesrosiersPublished in: International forum of allergy & rhinology (2020)
Low-dose azithromycin is a therapeutic option with few side effects. Its use can show favorable clinical outcomes in this difficult-to-treat population, especially if patients are AERD-negative.
Keyphrases
- low dose
- double blind
- end stage renal disease
- ejection fraction
- minimally invasive
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- open label
- randomized controlled trial
- high dose
- placebo controlled
- coronary artery bypass
- clinical trial
- coronary artery disease
- acute coronary syndrome
- patient reported
- percutaneous coronary intervention
- drug induced